Journal
ANTIVIRAL RESEARCH
Volume 192, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2021.105116
Keywords
Herpes simplex virus type 1; Matrix metalloproteinase 14; Neurodegeneration; Alzheimer's disease; Antiviral target
Categories
Funding
- Ministerio de Ciencia, Innovacion y Universidades [SAF201785747R]
Ask authors/readers for more resources
Growing evidence suggests that chronic or latent infection of the central nervous system, particularly from Herpes simplex virus type 1 (HSV-1), may be associated with Alzheimer's disease. The study highlights the potential role of MMP-14 in controlling HSV-1 infection efficiency and reducing neurodegenerative effects induced by the virus.
Growing evidence supports that chronic or latent infection of the central nervous system might be implicated in Alzheimer's disease (AD). Among them, Herpes simplex virus type 1 (HSV-1) has emerged as a major factor in the etiology of the disease. Our group is devoted to the study of the relationship among HSV-1, oxidative stress (OS) and neurodegeneration. We have found that HSV-1 induces the main neuropathological hallmarks of AD, including the accumulation of intracellular amyloid beta (A beta), hyperphosphorylated tau protein and autophagic vesicles, that OS exacerbates these effects, and that matrix metalloproteinase 14 (MMP-14) participates in the alterations induced by OS. In this work, we focused on the role of MMP-14 in the degenerative markers raised by HSV-1 infection. Interestingly, we found that MMP-14 blockage is a potent inhibitor of HSV-1 infection efficiency, that also reduces the degeneration markers, accumulation of A beta and hyperphosphorylated tau, induced by the virus. Our results point to MMP-14 as a potent antiviral target to control HSV-1 infection and its associated neurodegenerative effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available